Alopecia Areata: Current And Emerging Therapies

Research cited in this study 65

1. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial Journal of the American Academy of Dermatology · 2025
2. Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2 SKIN The Journal of Cutaneous Medicine · 2025
3. Alopecia Areata: From Immunopathogenesis to Emerging Therapeutic Approaches Frontiers in Immunology · 2025
4. Alopecia Areata Nature Reviews Disease Primers · 2025
5. Ivarmacitinib for the Treatment of Adults with Severe Alopecia Areata: Results from a Phase 3 Trial Journal of the American Academy of Dermatology · 2025
6. Network Meta-Analysis of FDA-Approved JAK Inhibitors for Alopecia Areata With at Least 50% Hair Loss Per SALT Score Journal of the American Academy of Dermatology · 2025
7. From Mechanisms to Therapies: Current Advances and Breakthroughs in Alopecia Areata Immunopathology Frontiers in Immunology · 2025
8. Complete Hair Regrowth in a Patient With Severe Alopecia Areata Treated With Deucravacitinib Clinical and Experimental Dermatology · 2025
9. Oral Minoxidil Treatment of Alopecia Areata Journal of the American Academy of Dermatology · 2025
10. Combination Oral Minoxidil and Baricitinib Treatment of Alopecia Areata Journal of the American Academy of Dermatology · 2025
11. Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023 Dermatology and Therapy · 2025
12. Friend Or Foe: A Systematic Review Of Dupilumab And Alopecia Areata Journal of the American Academy of Dermatology · 2025
13. Janus Kinase Inhibitors for Alopecia Areata: A Review of Clinical Data Frontiers in Immunology · 2025
14. Successful Treatment of Severe Diffuse Alopecia Areata with Abrocitinib Anais Brasileiros de Dermatologia · 2025
15. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
16. Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients Pediatric Dermatology · 2025
17. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
18. Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study Journal of Dermatological Treatment · 2025
19. Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature Dermatology Practical & Conceptual · 2024
20. Oral Abrocitinib for Treatment of Refractory Alopecia Areata: A Retrospective Study Journal of the American Academy of Dermatology · 2024
21. British Association of Dermatologists Living Guideline for Managing People with Alopecia Areata 2024 British Journal of Dermatology · 2024
22. Alopecia Areata Exhibits Cutaneous And Systemic OX40 Activation Across Atopic Backgrounds Allergy · 2024
23. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
24. Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients Australasian Journal of Dermatology · 2024
25. Dupilumab Therapy for Alopecia Areata: A Case Series and Review of the Literature Journal of Dermatological Treatment · 2024
26. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
27. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
28. Ritlecitinib: First Approval Drugs · 2023
29. Successful Treatment of Alopecia Universalis With Abrocitinib: A Case Report Journal of Dermatological Treatment · 2023
30. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
31. Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib Journal of cosmetic dermatology · 2023
32. Baricitinib for the Treatment of Alopecia Areata Drugs · 2023
33. Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review Clinical drug investigation · 2023
34. Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population JAMA Dermatology · 2023
35. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
36. The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity Journal of the European Academy of Dermatology and Venereology · 2023
37. Rapid Hair Regrowth in an Alopecia Universalis Patient With Deucravacitinib: A Case Report SAGE open medical case reports · 2023
38. Alopecia Areata and Risk of Atopic and Autoimmune Conditions: Population-Based Cohort Study Clinical and Experimental Dermatology · 2022
39. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
40. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
41. Identification of Novel Step-Up Regimen of Intralesional Triamcinolone Acetonide in Scalp Alopecia Areata Based on a Double-Blind Randomized Controlled Trial Dermatologic Therapy · 2020
42. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
43. Efficacy of Different Concentrations of Intralesional Triamcinolone Acetonide for Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the American Academy of Dermatology · 2019
44. Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata JAMA Dermatology · 2019
45. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
46. Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children Journal of the American Academy of Dermatology · 2018
47. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata JAMA Dermatology · 2018
48. An Integrated Model of Alopecia Areata Biomarkers Highlights Both TH1 and TH2 Upregulation Journal of Allergy and Clinical Immunology · 2018
49. Nail Changes in Alopecia Areata: An Update and Review International Journal of Dermatology · 2018
50. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
51. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
52. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
53. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
54. Pulse Corticosteroid Therapy With Oral Dexamethasone for the Treatment of Adult Alopecia Totalis and Universalis Journal of the American Academy of Dermatology · 2016
55. A Systematic Review of Pulse Steroid Therapy for Alopecia Areata Journal of the American Academy of Dermatology · 2016
56. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
57. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
58. Imbalance of T-Helper 17 and Regulatory T Cells in Patients with Alopecia Areata The Journal of Dermatology · 2015
59. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
60. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
61. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012
62. Alopecia Areata Update Journal of the American Academy of Dermatology · 2010
63. Placebo-Controlled Oral Pulse Prednisolone Therapy in Alopecia Areata Journal of the American Academy of Dermatology · 2005
64. 308-Nm Excimer Laser Therapy in Alopecia Areata Journal of the American Academy of Dermatology · 2004
65. Clobetasol Propionate 0.05% Under Occlusion in the Treatment of Alopecia Totalis/Universalis Journal of the American Academy of Dermatology · 2003